spot_img

Italfarmaco and Medis Announce Exclusive Distribution Agreement for Givinostat in 17 Central and Eastern European Countries including the Baltic States

Medis will have exclusive distribution rights in 17 EU and non-EU countries for givinostat once approved Regulatory approvals for givinostat as a treatment...

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General...

Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in MDD subjects...

Top Stories

admin

Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization...

MELBOURNE, Australia and PORTO ALEGRE, Brazil, March 18, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the Brazilian Health Regulatory Agency...
admin

Alto Ingredients, Inc. Enters into Letter Agreement with Bradley L. Radoff...

PEKIN, Ill., March 18, 2025 (GLOBE NEWSWIRE) -- Alto Ingredients, Inc. (NASDAQ: ALTO), a leading producer and distributor of specialty alcohols, renewable fuels and essential ingredients, today announced that it has entered into a letter agreement (the “Letter Agreement”) with Bradley L. Radoff and Michael Torok (collectively...

Most Popular

People

Only In Your State Launches Navigable Excursion Tool: Routes

admin
People

Global Bioactive Ingredients Market Set to Reach USD 451.3 Billion by...

admin
People

10th Int’l Strawberry Symposium Unveils “Yanmei-1” variety

admin
People

Premium Garage Doors from Europe: Ryterna Names Calgary Garage Door Fix...

admin
People

ELF Shareholders with Large Losses Should Contact Robbins LLP for information...

admin
admin

Pacira BioSciences Confirms Receipt of Director Nominations from DOMA Perpetual

-- No Shareholder Action Required at This Time -- PARSIPPANY, N.J., March 14, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today confirmed that DOMA Perpetual Capital...
admin

Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER...

- Continued favorable safety profile for DYNE-251 - - DELIVER Registrational Expansion Cohort is fully enrolled; data from this cohort planned for late 2025 - - Potential for...
spot_img

Category

CHiQ Partners with Olympic Champion Andreas Wellinger Team Up to Conquer...

admin

FUJIFILM Business Innovation Enhances Business Solutions to Support Office Digital Transformation...

admin